Diseases of the Chest “cut its teeth” in the emerging field of TB in the 1930s, when the complex milieu included poor social conditions, improved understanding of epidemiology, changing dietary habits, and, later, the advent of chemotherapeutic agents, such as sulfa drugs and other more toxic agents. Diseases of the Chest embraced this theme from many different aspects and provided a wonderful vehicle for practitioners to improve the management of this complex disease. Several papers described new individual agents and their activity against Mycobacterium tuberculosis; however, it was the work by Frederic J. Hughes and colleagues1 in 1952 that raised the possible use of a combined intermittent regimen in the treatment of nonmiliary pulmonary TB. The appreciation that optimal therapy for TB would require a regimen not previously considered was beginning to emerge in the late 1940s, with this Colorado-based group conducting an intriguing comparison of daily vs every-3-days combination of two agents, streptomycin and para-aminosalicyclic acid (PAS). The balance of eradication of the tubercle bacillus and the acknowledged toxicity profile of these agents was clearly crucial. Following a well-controlled, although numerically small study, these researchers established that intermittent streptomycin with daily PAS provided good clinical responses and reduced development of drug resistance.